| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | lapatinib | gCSI | pan-cancer | AAC | 0.24 | 1e-05 |
| mRNA | Erlotinib | gCSI | pan-cancer | AAC | 0.24 | 3e-05 |
| mRNA | Erlotinib | CCLE | pan-cancer | AAC | 0.19 | 6e-05 |
| mRNA | Cetuximab | GDSC1000 | pan-cancer | AAC | 0.14 | 6e-05 |
| mRNA | FK866 | GDSC1000 | pan-cancer | AAC | -0.12 | 0.0001 |
| mRNA | GSK269962A | GDSC1000 | pan-cancer | AAC | -0.13 | 0.0001 |
| mRNA | LAQ824 | GDSC1000 | pan-cancer | AAC | -0.13 | 0.0002 |
| mRNA | Obatoclax Mesylate | CTRPv2 | pan-cancer | AAC | -0.12 | 0.0003 |
| mRNA | Vorinostat | GDSC1000 | pan-cancer | AAC | -0.11 | 0.0005 |
| mRNA | lapatinib | CCLE | pan-cancer | AAC | 0.16 | 0.0005 |